Reading time: ~2 min · Part of the free certification in peptide science
Each peptide family has a safety profile consistent with its mechanism. Knowing it makes it possible to anticipate, contextualize and communicate the expected events.
- Incretin agonists (GLP-1, dual, triple): the most frequent events are gastrointestinal (nausea, early satiety, constipation or diarrhea), consistent with gastric slowing and typically dependent on the titration speed. Gradual titration is the main tolerability strategy.
- GH secretagogues (GHRH/GHRP): because of their effect on the GH/IGF-1 axis they may be associated with fluid retention, arthralgias, paresthesias or carpal tunnel-type symptoms, and with changes in insulin sensitivity; GHRP-6 stands out for appetite stimulation.
- Melanocortins (Melanotan, PT-141): nausea and flushing are common; MC1R agonists induce darkening of the skin and nevi, which requires dermatological monitoring.
- Repair peptides: their human safety profile is less characterized because preclinical evidence predominates; the uncertainty is, in itself, information to communicate.
The safety of a mechanism is predictable from its pharmacodynamics: where there is a potent effect, there are usually off-target effects or physiological consequences of the effect itself. Anticipating them is more useful than reacting to them.
Catalogue compounds mentioned in this lesson
Take the module 10 quiz and earn your certificate
The certification is free: read the lessons, pass each module quiz and the final exam, and download your PDF certificate with a verifiable ID.
Go to the quiz →Educational content for scientific purposes. It distinguishes preclinical from clinical evidence and is not medical advice, diagnosis or a recommendation for use. NeoPeptidos products are sold labelled for research use only (RUO).